RPRX — Royalty Pharma plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802768 ·
Last close
$58.21
Market Cap
$25.92B
52W High
$64.38
52W Low
$33.97
ADV30
2,949,063
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 674,141,000 | — | 133,119,000 | 17,883,000 | 19,819,771,000 | 811,986,000 | 10,034,057,000 |
| Mar 2026 | 630,576,000 | — | 632,481,000 | 294,690,000 | 19,815,415,000 | 586,395,000 | 9,878,582,000 |
| Dec 2025 | 621,990,000 | — | 388,382,000 | 214,205,000 | 19,620,780,000 | 618,696,000 | 9,905,841,000 |
| Sep 2025 | 609,291,000 | — | 427,156,000 | 288,217,000 | 19,347,280,000 | 938,944,000 | 9,726,419,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,976,457,000
Investing CF
$-2,513,702,000
Financing CF
$-282,677,000
CapEx
—
Dividends Paid
$-399,061,000
Buybacks
$-321,773,000
EPS Diluted TTM
$1.61
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$2,459,089,000
Inventory
—
Receivables
$31,474,000
ST Investments
$914,454,000
EBIT TTM
$1,710,940,000
Pretax Income TTM
$1,349,866,000
Interest Exp TTM
$361,074,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,535,997,952
EBITDA
$1,557,374,976
Free Cash Flow
$-1,195,372,160
Enterprise Value
$37,175,586,816
Total Cash
$836,985,984
Total Debt
$8,961,892,352
Shares Out
445,277,344
Trailing EPS
$1.86
Book Value
$15.33
ROE
14.0%
ROA
5.1%
Div Yield
1.60%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,378,193,000 | 1,559,518,000 | 770,947,000 | 19,620,780,000 | 9,905,841,000 | 6,476,900,000 | 2,489,823,000 |
| Dec 2024 | 2,263,576,000 | 1,292,444,000 | 858,983,000 | 18,222,715,000 | 7,880,349,000 | 6,946,581,000 | 2,768,986,000 |
| Dec 2023 | 2,354,554,000 | 1,492,150,000 | 1,134,834,000 | 16,381,851,000 | 6,297,562,000 | 6,526,497,000 | 2,987,802,000 |
| Dec 2022 | 2,237,215,000 | 922,892,000 | 42,832,000 | 16,813,466,000 | 7,288,093,000 | 5,628,150,000 | 2,143,980,000 |
TTM Snapshot
Revenues TTM
$2,242,713,000
NetIncome TTM
$998,101,000
OpCashFlow TTM
$0
Assets (Latest)
$19,620,780,000
Forward EPS
$5.73
Max Pain — expiry 2026-12-18
max pain strike: $42.50 · spot: $58.49 · call oi: 5,397 · put oi: 977
Expected Move to 2026-12-18:
±$5.97
(10.21%) —
implied range
$52.52 –
$64.47
· ATM straddle on $57.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | $25.86B | $35.80 | — |
| INSM | INSMED Inc | $25.73B | $117.83 | — |
| ZTS | Zoetis Inc. | $29.36B | $71.05 | — |
| GMAB | GENMAB A/S | $21.72B | $35.32 | — |
| VTRS | Viatris Inc | $20.48B | $17.83 | — |
News headlines (Yahoo Finance, 1h cache)
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
2026-09-25 06:02 · Yahoo
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run
2026-09-23 11:14 · Yahoo
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
2026-09-23 10:16 · Yahoo
Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
2026-09-15 20:30 · Yahoo
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
2026-09-10 18:20 · Yahoo
Royalty Pharma to present at upcoming investor conferences
2026-09-09 20:05 · Yahoo
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
2026-09-04 23:05 · Yahoo
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough
2026-09-01 17:54 · Yahoo
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
2026-08-25 18:24 · Yahoo
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
2026-08-13 22:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.